Drug Profile
LD22-4
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Motility
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous)
- 18 Sep 2006 Phase-I clinical trials in Age-related macular degeneration in USA (Intravitreous)
- 15 May 2006 Preclinical trials in Age-related macular degeneration in USA (Unspecified)